Was this a head-to-head trial?

Not in the strict sense. It was a dose-finding trial with an open-label semaglutide reference arm, which is weaker evidence than a blinded comparison.

Why do quoted survodutide numbers vary so much?

Figures from this type 2 diabetes trial are frequently mixed with those from a separate 46-week trial in a different population without diabetes.

What does the glucagon receptor add?

Increased energy expenditure and mobilisation of hepatic fat — the same rationale as retatrutide's third receptor.

GLP-1 & Incretin Science

The Survodutide Comparison, Read Properly

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Blüher and colleagues compared survodutide against placebo and an open-label semaglutide arm in adults with type 2 diabetes, published in Diabetologia in 2024. The semaglutide arm was open-label and the trial was dose-finding, which makes this weaker evidence than a blinded head-to-head.

Key facts

Compound: Survodutide (BI 456906)
Class: GLP-1 / glucagon dual agonist
Comparators: Placebo and open-label semaglutide
Population: Adults with type 2 diabetes
Published: Diabetologia 2024 (PMID 38095657)
Correction issued: Diabetologia 2024 (PMID 38349400)
Design: Dose-response, not a pivotal head-to-head

What the trial was for

Dose-response. Its primary purpose was establishing how HbA1c and body weight reduction varied across survodutide doses — a dose-finding exercise. The semaglutide arm was included as a reference point, not as the trial's reason for existing.

Why open-label matters

Participants and investigators knew who was receiving semaglutide. Blinding exists because knowledge of assignment influences reported outcomes, adherence and adverse event reporting. An open-label comparator arm is informative context; it is not the same evidential object as a double-blind randomised comparison, and results from it should carry that qualification.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The confusion in circulation

Figures from this trial are routinely mixed with figures from a separate 46-week trial in participants with overweight or obesity without diabetes. Those are different populations, different durations and different endpoints. A number quoted without its population and duration attached cannot be checked, and in this compound's coverage that happens constantly.

Why a correction was published

Diabetologia issued a correction to the paper in 2024. Corrections are routine and usually minor, but they are part of the published record and citing the original without checking whether one exists is how errors persist. This site's citation checking now surfaces them.

What the glucagon component contributes

Survodutide adds glucagon receptor agonism to GLP-1 activity, which raises energy expenditure and mobilises hepatic fat. It is the same rationale behind retatrutide's third receptor, and it is why compounds in this class are also studied in metabolic liver disease rather than weight alone.

What it is not

Survodutide is investigational. Semaglutide is a licensed medicine. Neither is related to research material, and comparing their trial results has no bearing on anything supplied here.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Was this a head-to-head trial?: Not in the strict sense. It was a dose-finding trial with an open-label semaglutide reference arm, which is weaker evidence than a blinded comparison.
Why do quoted survodutide numbers vary so much?: Figures from this type 2 diabetes trial are frequently mixed with those from a separate 46-week trial in a different population without diabetes.
What does the glucagon receptor add?: Increased energy expenditure and mobilisation of hepatic fat — the same rationale as retatrutide's third receptor.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum